Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University
News May 07, 2008
Regulus Therapeutics LLC and Isis Pharmaceuticals, Inc. formed to discover, develop, and commercialize microRNA (miRNA) therapeutics, announced that it has obtained exclusive rights from Stanford University to worldwide patent applications covering methods and compositions for antagonizing miR-181a to regulate immune responses.
Changes in miR-181a levels have been shown to modify the response of immune cells such as T lymphocytes to specific stimuli and its antagonism could lead to a new way to treat inflammatory diseases.
“We are excited about obtaining exclusive rights to this intellectual property, as it is another step in Regulus’ overall strategy to build a broad and leading platform of technology and intellectual property for the development of miRNA therapeutics, and adds to our already dominant patent position,” said Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus.
“At Regulus, we are aggressively exploring a variety of therapeutic areas including viral, metabolic, and inflammatory diseases. Access to this intellectual property allows us to apply our expertise in the biology and potential therapeutic uses of miRNAs to develop novel treatments for inflammatory diseases.”
Analytical Tool Predicts Disease-Causing GenesNews
Predicting genes that can cause disease due to the production of truncated or altered proteins that take on a new or different function, rather than those that lose their function, is now possible thanks to an international team of researchers that has developed a new analytical tool to effectively and efficiently predict such candidate genes.
Gene Regulator May Contribute to Protein Pileup in Exfoliation GlaucomaNews
Researchers are seeking factors that contribute to protein pileup in exfoliation glaucomaREAD MORE
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE